ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

St. Jude Children’s wins NCI contract for Pediatric Preclinical Testing Program.

November 12, 2004

NCI May Give Up Positions From Other Programs To Meet Mandate For CTP Slots

October 19, 1979

HCT Survivors More Likely To Show Heart Disease Risk Factors

October 26, 2012

NCI Funds New Centers At Stanford, Baylor.

June 15, 2007

In Brief: Beahrs, Murphy, Quan Honored By SSO; AACR Award Mulligan, Wiggler, Sporn, Witte

March 29, 1991

Seer Data On Cancer Incidence Among Minorities Published

May 10, 1996